|
|
[Report]
The World Generic Markets Report 2008 (6th Edition)
Published: 2007/12
|
|
 |
|
|
|
Table of Contents
Volume I: Global Overview and Company Profiles
FOREWORD
- Current Issues in the USA
- Authorised generics
- FTC investigation
- Moves in Congress
- PhRMA responds
- GPhA responds
- More studies, more arguments
- Senate Committee Discusses Regulatory Delays, Authorised Generics,
Citizen Petitions
- Gary Buehler
- Jon Leibowitz
- Heather Bresch
- Shared exclusivity
- Industry consolidation
- Where next in the USA?
- Where next in Europe?
- Biosimilars
- Political pressure
- Access to Life-Saving Medicine Act (H.R. 6257)
- Biologics Price Competition and Innovation Act of 2007 (S.1695)
- House Committee on Oversight and Government Reform
- Henry Waxman
- Access to Generic Drugs in the Developing World: WTO Agreement
- 2003 Agreement
- TRIPS patent ruling on least-developed countries, 2002
- Canada
- European Union
- European Parliament pushes for greater access to generic drugs
- Thailand
- Brazil
- Clinton Foundation
- PEPFAR
- Current Issues in the European Union
- European Union Regulatory Reforms Take Effect, November 2005
- Product definition
- Data exclusivity
- European Commission regulations for paediatric medicines introduced in
2007
- Enlargement of the European Union
- Parallel Trade in the enlarged EU
- The widening influence of Indian companies
- Prospects for Future Growth
- Relative strength of intellectual property laws
- Pricing/reimbursement regimes
- Prescriber/patient habits
- Major Generic Manufacturers
- Actavis.
- Introduction
- Background
- Products
- Own-label Products
- Third-Party Products
- Financials
- Major developments
- Actavis building new R&D centre in Iceland
- Actavis opens Albania office
- Actavis opens a representative office in Vietnam
- Mergers, acquisitions and agreements
- Actavis partners with Germany' s AOK
- Actavis acquires Indian manufacturing plant
- Actavis and Orchid form European licensing and distribution alliance
- Actavis strengthens its position in India
- Actavis acquires Abrika
- Actavis purchases majority stake in Russian manufacturing facility
- Actavis to acquire Romanian generic oncology specialist, Sindan
- Actavis acquires Alpharma' s Human Generics business
- Fako
- Actavis acquires Denmark' s Ophtha
- Actavis acquires Keri Pharma Generics
- Actavis acquires Higia
- Actavis sells Bulgarian API plant, retains dosage form capacity
- Actavis acquires Amide Pharmaceutical
- Acquisition of Pharma Avalanche
- Actavis expands presence in India
- Actavis acquires Biovena
- Apotex
- Introduction
- Background
- Products
- Financials
- Major developments
- Rwanda issues first notification under WTO Paragraph 6 system
- Akorn and Apotex sign ophthalmics agreement
- Orchid Chemicals & Pharmaceuticals
- BioGeneriX
- Litigation
- Plavix (clopidogrel)
- Allergan sues Apotex for infringement of brimonidine tartrate patents
- Apotex invalidates amlodipine patent, setting off stream of activity
- Unigene/Upsher-Smith file patent infringement lawsuit against Apotex
- Allergan wins Acular patent infringement lawsuit
- Aspen Pharmacare
- Introduction
- Background
- Products
- HIV/AIDS drugs
- South African government ARV tender
- Financials
- Major developments
- Pharmaceutical firms form new South African industry association
- Mergers, acquisitions and agreements
- Acrux enters oestradiol marketing agreement with Aspen Pharmacare in
Australia
- Darunavir access plan with Tibotec
- Lupin and Aspen terminate TB MoU
- Roche
- Oseltamivir
- Saquinavir
- Bristol-Myers Squibb
- Gilead
- Matrix Laboratories
- Fine Chemicals Corporation
- William J Clinton Presidential Foundation
- Eli Lilly
- GlaxoSmithKline
- Strides Arcolab
- Barr Pharmaceuticals
- Introduction
- Background
- Products
- Financials
- Major developments
- Barr and Apotex launch Canada' s first generic oral contraceptive
- US Supreme Court denies review of tamoxifen citrate antitrust lawsuit
- Barr successfully acquires Pliva
- Barr and Shire enter three agreements
- Barr/Pliva sign agreement to develop and market generic version of
G-CSF in US and Canada
- Barr gains generic fentanyl agreement
- Cipla
- Introduction
- Background
- New Plant Announced, June 2006
- Products
- Financials
- Major developments
- HIV/AIDS
- Thai government in talks with Cipla over antiretroviral ingredients
- AHF and Cipla quarrel over AIDS drugs prices
- Clinton Foundation and UNITAID announce agreements to reduce ARV prices
- Compulsory licensing in Malaysia
- South African antiretroviral tender
- Mergers, acquisitions and agreements
- Akorn signs contract with Cipla for injectable ANDA product
- Akorn and Cipla sign agreement for oral organ transplant rejection drug
- Cipla enters malaria agreement with DNDi
- Cipla to supply API to IVAX
- Cipla Medpro sold to Enaleni
- Pentech Pharmaceuticals
- Avestha Gengraine Technologies
- Morton Grove Pharmaceuticals
- Watson Pharmaceuticals
- Stada, Hexal and Fujisawa
- Dr Reddy' s Laboratories
- Introduction
- Background
- Products
- Financials
- Segment Data
- Active pharmaceutical ingredients and intermediates (API)
- Formulations
- Generics
- Custom pharmaceuticalservices (CPS)
- Critical care andbiotechnology
- Major developments
- Dr Reddy' s opens Manila office
- Dr Reddy' s begins operations in Nigeria
- Dr Reddy' s joins USP' s Pharmaceutical Ingredient Verification Programme
- Dr Reddy' s and Torrent sign Russian lisinopril agreement
- Dr Reddy' s acquires betapharm
- Dr Reddy' s and Argenta announce R&D collaboration
- Dr Reddy' s signs agreement to acquire Roche' s Mexico API facility
- Perlecan formed as India' s first integrated drug-development company;
Dr Reddy' s invests and
- signs alliance
- Dr Reddy' s/Pharmascience sign multi-product agreement
- Dr Reddy' s and ICICI form ANDA partnership
- Trigenesis Therapeutics
- Dr Reddy' s Laboratories (Proprietary)
- BMS Laboratories and Meridian Health Care
- American Remedies and Cheminor Drugs
- Pliva
- Leiner Health Products
- Egis
- Introduction
- Background
- Products
- Financials
- Preliminary results for the year ended 30th September, fiscal 2007
- Fiscal 2006 results
- Major developments
- Hospira
- Introduction
- Background
- Products
- Financials
- Major Developments
- Mayne Pharma
- FTC sets conditions, clearing the way for Hospira' s acquisition of
Mayne Pharma
- Hikma and Hospira enter European marketing agreements
- Hospira announces strategic alliance with Pharmalink and Zuellig
Pharma in Asia
- KRKA
- Introduction
- Background
- Products
- EMEA recommends MA for Krka product
- Financials
- Major developments
- Facilities
- Slovenia
- Russia
- Poland
- Representative offices
- Litigation
- Simvastatin
- Atorvastatin
- Enalapril
- Lannett
- Introduction
- Background
- New facility leased, 2006
- Products
- Financials
- Major developments
- Lannett acquires unnamed API supplier
- PharmaSeed Bioservices
- Olive Healthcare
- Azad Pharma
- Wintac
- Orion Pharma
- Unichem Laboratories
- Jerome Stevens Pharmaceutical
- Merck Generics
- Introduction
- Background
- Alphapharm
- Generics (UK)
- Genpharm
- Merck Generics (South Africa)
- Merck Dura
- Dey Inc
- Products
- Financials
- Major developments
- Mylan agrees to acquire Merck Generics for 4.9 billion euros
- Glenmark and Merck Generics form European marketing agreement
- Merck KGaA purchases Spain' s Prasfarma
- NM Pharma
- Litigation
- Mylan
- Introduction
- Background
- Products
- Financials
- Segment Data
- Total Revenues by Geographic Region
- Major developments
- Mylan agrees to acquire Merck Generics for 4.9 billion euros
- Matrix Laboratories
- King Pharmaceuticals merger called off
- Par Pharmaceuticals
- Introduction
- Background
- Products
- Financials
- Major Developments
- Hana Biosciences licenses North American ondansetron rights to Par
Pharmaceutical
- IntelliPharmaCeutics announces equity investment by Par Pharmaceutical
- AstraZeneca/Par enter agreement for generic version of Toprol-XL
- Spectrum Pharmaceuticals
- Par divests FineTech
- Bradley and Par enter licensing agreement for Adoxa
- MN Pharmaceuticals
- Orchid Chemicals & Pharmaceuticals
- Perrigo
- Introduction
- Background
- Products
- Financials
- Major developments
- Perrigo divests two facilities
- Perrigo acquires Qualis
- Perrigo acquires generic dermatological products from Glades
- Dexcel Pharma Technologies
- Agis Industries
- Collaboration with Bentley Pharmaceuticals
- Litigation
- Adams receives notice of Paragraph IV certification against patents
for Mucinex SE
- Triamcinolone (Barr Laboratories)
- Connetics
- FTC investigation
- Phenylpropanolamine
- Pliva
- Introduction
- Background
- Products
- Financials
- Segment Results
- Revenues by Region
- Major developments
- Pliva to acquire ORCApharm
- Barr successfully acquires Pliva
- Pliva signs agreement with Unichem for new products in the US
- Uso Racional
- Pliva exits proprietary business
- Pliva' s AWD.pharma divests manufacturing plant
- Pliva subsidiary divests branded product, terminates agreements with
Legacy Pharma
- Pliva signs new bulk azithromycin supply agreement with Pfizer
- Ranbaxy
- Introduction
- Background
- Products
- Antiretrovirals
- Ranbaxy forms JV in South Africa to market antiretrovirals
- Gilead signs eight TDF agreements with Indian companies
- Financials
- Segment Data
- Geographic Segment
- Major developments
- Ranbaxy acquires dermatology brands from Bristol-Myers Squibb
- Ranbaxy signs first biosimilars agreement
- Ranbaxy signs new R&D agreement with GlaxoSmithKline
- Ranbaxy acquires Be-Tabs for US$70 million
- Ipca and Ranbaxy sign deal for US market
- Ranbaxy signs Canadian licensing and supply agreement
- Ranbaxy to acquire GSK' s Mundogen generic business in Spain
- Ranbaxy completes Terapia acquisition
- Ranbaxy forms strategic oncology partnership with Zenotech
- Ranbaxy to co-market Ferring' s desmopressin in India
- Ranbaxy and Nippon Chemiphar consolidate relationship
- Ranbaxy to market Lupin' s TB brands in Africa
- Ranbaxy acquires generic product portfolio from Efarmes
- UK Department of Health legal action settled
- ratiopharm
- Introduction
- Background
- BioGeneriX
- Merckle Biotec
- Merckle
- PulmoTec
- ratiopharm direct
- Products
- Financials
- Major developments
- German bribery investigation
- Mergers, acquisitions and agreements
- Hikma acquires ribosepharm from ratiopharm
- BioGeneriX and Neose update on biosimilar collaboration
- Orbus signs agreement with ratiopharm Canada
- IntelliPharmaCeutics enters generic agreements with ratiopharm
- Magnafarma
- BioGeneriX signs agreement with Cangene
- Ribosepharm
- Gedeon Richter
- Introduction
- Background
- Products
- Financials
- Segment Results
- Geographic Segment Data
- Major developments
- Gedeon Richter acquires Romania' s Dita Group
- Themis Medicare India starts trial production at Vapi site
- US deal with KV Pharmaceutical
- Consortium bid for Hungaropharma successful
- GZF Polfa
- Biogen International
- Sandoz
- Introduction
- Background
- Production Facilities
- Sandoz Canada to invest C$80 million in Boucherville facilities
- Products
- Financials
- Lek
- Major developments
- EU epoetin alpha approval
- Omnitrope approved in EU and USA
- Momenta enters expanded collaboration agreement with Sandoz
- Lek opens new facility in Slovenia
- Sandoz completes purchase of Hexal and Eon Labs
- Sabex
- Durascan
- Amifarma
- Sawai Pharmaceutical
- Introduction
- Background
- Products
- New government supply rules, 2006
- Financials
- Major developments
- Towa, Sawai and Nichi-iko sign agreement for stable supply of generic
products
- Medisa Shinyaku
- Nihon Schering' s Mobara factory
- Japan Generic Drug Research Group
- Stada Arzneimittel
- Introduction
- Background
- Products
- Financials
- Segment Data
- Geographic Segment Data
- Major developments
- Stada reorganises biosimilar projects; Hospira to acquire
erythropoietin rights
- Mergers, acquisitions and agreements
- Forum Bioscience Group
- Makiz
- Hemofarm
- Stada sells US subsidiary to DAVA
- ProStrakan signs branded generic agreement with Genus Pharmaceuticals
- Beijing Center-Lab Pharmaceutical, majority stake
- Advancis enters amoxicillin PULSYS agreement with Stada' s Clonmel
Healthcare
- Strides enters agreement with Stada in the US
- Stada acquires Portuguese generics supplier
- Orchid enters US market agreement with Stada Pharmaceuticals
- Stada acquires Nizhpharm
- Teva Pharmaceutical Industries
- Introduction
- Background
- Products
- Financials
- Segment Data
- Geographic Segment
- Major developments
- BioSante and Teva restart testosterone product development
- Teva and Synerx form US marketing partnership
- Teva signs biopharmaceuticals agreement with Procognia (Israel)
- Teva increases stake in Hualida
- Teva completes IVAX acquisition; Par and Barr benefit
- Teva and Barr sign agreement covering fexofenadine
- Teva and TransPharma sign transdermal drug delivery agreement
- Dorom
- Microbia
- Sicor
- Impax
- Litigation
- Federal appeals court upholds Lexapro patent decision
- Novartis' motion for preliminary injunction against Teva' s Lotrel
generics denied
- Court rules in Eisai' s favour over Aciphex ANDAs
- Pfizer wins Celebrex patent challenge by Teva
- Biovail reaches comprehensive settlement related to Wellbutrin XL
- Teva files patent infringement complaints against sertraline
manufacturers
- Teva and Pfizer reach agreements for anti-infective and cancer products
- Impax prevails in ALZA' s appeal over generic Ditropan XL
- Purdue and Teva agree deal to end OxyContin patent lawsuit
- Court of Appeals rules in Teva' s favour on Biaxin XL preliminary
injunction
- Alcon files patent infringement suit against Teva regarding Vigamox
- Esomeprazole magnesium
- Adderall
- Fexofenadine
- Modafinil
- Missouri AG alleges firms involved in AWP inflation scheme
- Donezepril hydrochloride
- Quetiapine fumarate
- Gatifloxacin tablets
- Lovenox
- Astellas/ITEM/King file lawsuit against Teva for Adenoscan patent
infringement
- Moexipril
- Towa Pharmaceutical
- Introduction
- Background
- Products
- Financials
- Major developments
- Towa, Sawai and Nichi-iko reach supply agreement
- Eisai' s lawsuit against manufacturers/distributors of generic Selbex
dismissed
- Japanese Generic companies form agreement for stable generic supply
- Watson Pharmaceuticals
- Introduction
- Background
- Products
- Generics Division
- Brand Division
- Distribution Division
- Financials
- Major developments
- Depomed enters promotion agreement with Watson
- Sandoz' ANDA for generic Toprol-XL approved further to agreement with
Watson
- Watson completes acquisition of Sekhsaria Chemicals
- Watson completes acquisition of Andrx
- Other acquisitions and collaborations
- Watson to distribute OxyContin authorised generic
- Interpharm and Watson commence ibuprofen manufacturing and supply
agreement
- Bupropion authorised generic agreement with GSK
- Winthrop Pharmaceuticals
- Introduction
- Background
- Czech Republic
- France
- Germany
- Portugal
- United Kingdom
- Products
- Financials
- Major Developments
- sanofi-aventis acquires 25% of Zentiva' s shares
- Wockhardt
- Introduction
- Background
- Wockhardt to build global manufacturing hub in India
- Products
- Financials
- Major developments
- Wockhardt to raise up to US$800 million to fund overseas acquisitions
- Pharmaceutical plants
- Barotiwala, India
- Luton, United Kingdom
- Aurangabad, India
- Joint Ventures
- Mergers, acquisitions and agreements
- Negma Laboratories
- Pinewood Laboratories
- Li-Taka Pharmaceuticals
- esparma GmbH
- CP Pharmaceuticals Ltd
- Ranbaxy
- Zentiva
- Introduction
- Background
- Products
- Financials
- Major developments
- Zentiva to acquire control of Eczacibasi' s generic pharmaceuticals
business
- Zentiva acquires Hungarian generic products from sanofi-aventis
- sanofi-aventis
- Sicomed
- Zydus Cadila
- Introduction
- Background
- Products
- Financials
- Major Developments
- Quimica e Farmaceutica Nikkho do Brasil
- Zydus acquires Japan' s Nippon Universal Pharmaceutical
- Zydus acquires Liva Healthcare
- Evolupharn and Aerocid
- Joint venture with Bharat Serums and Vaccines
- Joint venture with Mayne Pharma
- Venus Remedies
- Alliance with Mallinckrodt
- MoU with Zambon
- Alpharma France
- Merger into Cadila Healthcare
- Litigation
Volume II: National Markets
Overview
- Population
- GDP per capita
- Health Expenditure
- Total Pharmaceutical Expenditure
- Generic Pharmaceutical Expenditure
- Generic Market Projections
Australia
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Regulation
- Intellectual Property
- US Free Trade Agreement, Generic Amendments
- Parliament passes patent springboarding Bill
- Pricing & reimbursement
- Rise in Co-payment rates, 2005
- Therapeutic Group Premiums
- US Free Trade Agreement
- Government announces new pricing measures for newly listed drugs
- Government announces further PBS reforms, 2006
- Manufacturing
- Alphapharm
- Genepharm Australasia
- Mayne Pharma (Hospira)
- Sigma Pharmaceuticals Pty Ltd.
Brazil
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Production of Oral Generic Contraceptives & Hormones
- More Uniform Market Penetration Across all the Regions
- Unsustainable Reliance on Original HIV/AIDS Medicines
- Intellectual Property
- Lobbying Against Patent Extensions in the Pipeline System
- Deal Agreed to Reduce the Price of Abbott" s Kaletra
- Upcoming Patent Expiries
- Pricing & reimbursement
- Implications for the Industry
- Excessive Taxes on Drugs
- New Drug Discounts in the Public Sector
- Pricing of Generic Medicines
- Manufacturing
- ALANAC
- ALFOB
- Pro-Genericos
- Ache
- Americano de Farmacoterapia (FARMASA)
- Arrow (Erowlabs)
- Brainfarma
- Cimed
- Cristalia
- EMS Sigma Pharma
- Eurofarma
- Hipolabor
- LAFEPE
- Medley
- Neo Quimica
- Prati, Donaduzzi
- Teuto
- Uniao Quimica
- Multinational Producers of Generic Medicines In Brazil
- Apotex
- Mepha - ratiopharm
- Merck KGaA
- Ranbaxy
- Sandoz
Canada
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Study: generic savings not passed onto customers
- Outlook & Projections
- Intellectual Property
- New rules come into effect, October 2006
- Canada" s Access to Medicine Regime
- Pricing & reimbursement
- PMPRB issues first report on non-patented prescription drug prices
- Price increases between 2004 and 2005
- Study comparing drugs prices in Canada and the USA released
- Provincial Formularies
- The Quebec 15-year rule
- Ontario Bill 102
- Drug Insurance Programmes
- Manufacturing
- Apotex
- Genpharm
- Novopharm
- Orbus Pharma
- Pharmascience
- Ranbaxy
- ratiopharm
- Sandoz
France
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Outcomes of the New Reference Pricing System
- Increasing Prescribing of Generics
- Generic Drugs to Reduce Health Expenditure by 912 Million Euros in 2006
- France Transposes EU Pharmaceutical Directive
- Pharmacists Associations Agree New Generics Target for 2007
- Intellectual Property
- Supplementary Protection Certificates
- Pricing & reimbursement
- Pricing
- Pricing of Reimbursable Medicines in the Retail Pharmacy Market
- Price Revisions
- Pricing Activity
- Pharmacy Margins
- Reference Pricing (TFR)
- Pricing of Hospital Medicines
- Reimbursement
- Manufacturing
- Local Manufacturers
- Arrow Generiques
- Biogaran
- Bouchara-Recordati
- EG-Labo
- Merck Generiques
- Ranbaxy
- ratiopharm
- Sandoz
- Teva
- Winthrop
- Wockhardt
- Zydus France
Germany
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Intellectual Property
- Pricing & reimbursement
- Pricing
- Reimbursement
- AOK negotiates pharmaceutical discount contracts
- Generic Substitution Policies
- Compulsory Manufacturer Rebates
- AVWG, 2006
- Manufacturing
- 1A Pharma GmbH
- AbZ-Pharma GmbH
- Acceco Arzneimittel GmbH
- Aliud Pharma
- Actavis Deutschland
- AWD.pharma
- Basics
- betapharm
- CT-Arzneimittel
- Heumann Pharma Generics/Torrent Pharmaceuticals
- Hexal
- Hospira Deutschland GmbH
- Merck Dura
- Neuraxpharm
- ratiopharm
- Ribosepharm
- Sandoz
- Stada Arzneimittel
- Teva Generics
- Winthrop Arzneimittel
Italy
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Intellectual Property
- National Supplementary Protection Certificate
- Pricing & reimbursement
- EU Directive on the Transparency of Pricing & Reimbursement
- Reimbursement
- Manufacturing
- ASSOGENERICI
- Local Manufacturers
- Angenerico
- DOC Generici
- Eurogenerici
- Hexan
- Merck Generics Italia
- Pliva Pharma
- Ranbaxy
- ratiopharm Italia
- Sandoz
- Teva Pharma Italia
Japan
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Generic substitution plans
- Outlook & Projections
- Regulations
- Intellectual Property
- Data Exclusivity
- Exclusion of Use
- Patent term extensions
- Pricing & reimbursement
- Yakkasa
- Price reductions
- Generic drug pricing
- Manufacturing
- MHLW Stable Supply Requirements, 2006
- Overseas players
Netherlands
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Intellectual Property
- Pricing & reimbursement
- Manufacturing
- Actavis
- Centrapharm BV
- Disphar International BV
- Katwijk Farma BV
- Merck Generics
- Pharmachemie BV
- Ratiopharm Nederland
- Sandoz
Russia
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Intellectual Property
- Pricing & reimbursement
- Drug Pricing
- DLO, Federal Drug Supply System
- Manufacturing
- Akrikhin
- Bryntsalov A
- JSC Farmacon
- Grindex Rus
- KRKA
- Makiz
- Nizhpharm
- Otechestvennye Lekarstva (Erka Farm)
- Pharmstandard
- Veropharm
- Yugrafarm
- ZiO Zdorovje
Spain
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Biosimilars" Substitution, Not a Viable Option in Spain
- Regional INN Prescribing
- SWOT
- Intellectual Property
- European Supplementary Protection Certificate
- Pricing & reimbursement
- Co-Payments
- RPS Analysis
- Generic Pricing
- Manufacturing
- Local Manufacturers
- Adamed
- Alter
- Barr
- Cantabria Pharma
- Cinfa
- Combino Pharm
- DOMAC
- Dr Reddy' s
- Kern Pharma
- Mabo-Farma
- Merck
- Normon
- Pharmagenus
- Ranbaxy
- ratiopharm
- Sandoz
- Stada
- Teva
Switzerland
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- OKP Market Data, 2006
- Outlook & Projections
- Intellectual Property
- Pricing & reimbursement
- Generic pricing
- Generic pricing survey, 2006
- Generic/Brand price comparisons, 2007
- Generic reimbursement
- Manufacturing
- Cimex
- Helvepharm
- Mepha Pharma
- Sandoz Pharmaceuticals
- Spirig
- Streuli Pharma
United Kingdom
- Introduction
- Pharmaceutical Market
- Market Structure
- NHS Prescription Medicines Market
- Generic Market
- Size
- Generic Prescribing
- Outlook & Projections
- Regulation
- Marketing Authorisations in 2006
- Intellectual Property
- Supplementary Protection Certificates
- Pricing & reimbursement
- Pricing
- Unbranded Generic Pricing
- 2005 generics reimbursement scheme
- Generic price reductions for four major drugs
- DOH Holds consultations regarding branded generics in the PPRS
- Reimbursement
- Investigations into price fixing
- Department of Health
- Goldshield, Ranbaxy and Merck settle DOH claims
- Serious Fraud Office
- Manufacturing
- Actavis
- Arrow Generics
- Bristol Laboratories
- Crescent Pharma
- Dr Reddy' s
- Focus Pharmaceuticals
- Generics (UK)
- Genus Pharmaceuticals
- Goldshield Pharmaceuticals
- Kent Pharmaceuticals
- Perrigo
- Pliva Pharma (Barr Laboratories)
- Ranbaxy
- ratiopharm
- Rosemont Pharmaceuticals
- Sandoz
- Teva Pharmaceuticals
- Winthrop Pharmaceuticals
- Wockhardt
USA
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Wal-Mart begins generic drug price war?
- FTC reports summary of pharmaceutical company agreements filed in
FY2006
- Outlook & Projections
- Intellectual Property
- Hatch-Waxman
- Hatch Waxman reform, 2003
- Bolar Amendment
- Patent Reform Act 2007
- Wider patent reform?
- Major Product Approvals
- Generic Initiative for Value and Efficiency (GIVE)
- ANDAs Approved in 2006
- ANDAs Approved in 2007 (to September)
- Forthcoming Patent Expiries
- Pricing & reimbursement
- Public Drug Procurement
- Medicaid
- Average Wholesale Price (AWP)
- Medicare
- H.R.1 (Medicare Prescription Drug, Improvement, and Modernization Act
of 2003)
- State pricing/reimbursement moves
- California drug plan signed into law
- Manufacturing
Sources
Directory
- Regulators
- Industry Associations
|
|
|
|
|
|
|
[Report]
The World Generic Markets Report 2008 (6th Edition)
Published: 2007/12
|
Published by : Espicom Business Intelligence  |
|
|
Price:
|
Product Code : ES58554 |
|
|
Please inform me when related publications are released
|
|
|
View Cart
